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Introduction
Two of the most severe and common chronic diseases, cancer
and HIV/AIDS, result in heightened activation of the hypothal-
amic–pituitary–adrenal (HPA) axis and therefore chronically
increased blood cortisol concentration.1–3 The long-term effects
of raised cortisol include decreased capacity of the cellular
immune response,4 chronic inflammation due to glucocorticoid
insensitivity,5 and increased muscle catabolism.6,7 All these
effects result in chronically decreased quality of life. Considering
the high cost of most commercial (synthetic) medicines prescribed
for symptomatic treatment, it is of great importance to find a less
expensive treatment for these debilitating symptoms. A natural
remedy, Sutherlandia frutescens, has been used in traditional
medicine in South Africa for many decades, for the treatment of
stress-related illnesses.8,9
Some of the components of the Sutherlandia frutescens plant,
identified through chemical analyses,10–13 include L-canavanine,
gamma-aminobutyric acid (GABA) and pinitol. The individual
effects of these compounds have been illustrated in previous
studies on rats: L-canavanine had anti-viral14 and anti-cancer
actions,15,16 and was proved to be a selective inhibitor of inducible
nitric oxide synthase,17 which has been used effectively to treat
endotoxic shock in rats.11 GABA is an inhibitory neurotransmitter
and has mood-elevating properties. Pinitol has anti-inflamma-
tory properties.18 Although the individual actions of these sub-
stances are known, their combined palliative effects in one com-
pound have not been investigated before. Nevertheless, a
toxicology study in vervet monkeys19,20 has shown that Suther-
landia leaves, even at nine times the recommended dose for
humans on an equivalent per mass basis, had no toxic or any
other side effects with regard to haematological and biochemical
parameters measured.
The native words for this herb, motlepelo (Sotho for ‘bringing
back the heart’), insiswa (an ancient Zulu word meaning ‘the one
which dispels darkness’) and unwele (Zulu for ‘hair ’ — alluding
to the fact that the plant stops people from ‘pulling out their hair ’
with distress) are indicative of the main effect claimed — to
relieve symptoms such as irritability, anxiety and depression.
Although much anecdotal evidence exists to validate this herb as
having medicinal properties,8,9 to our knowledge, no scientific
proof exists of its action.
Much anecdotal evidence suggests a stress-relieving effect of the
Sutherlandia frutescens herb. We investigated this in a model of
chronic intermittent immobilization stress in 40 adult male Wistar
rats. A warm water extract of Sutherlandia leaves (4 mg/ml) was
used as treatment and isotonic saline as placebo, both injected
intraperitoneally. The four experimental groups were: a) control +
treatment (CS); b) control + placebo (CP); c) immobilization +
treatment (IS) and d) immobilization + placebo (IP). After 28 days,
resting blood corticosterone, testosterone, interleukin (IL)-6 and
tumor necrosis factor (TNF)- concentrations were measured.
Data were analysed with two-way ANOVA. Immobilization stress
resulted in significantly increased corticosterone concentrations in
IP vs CP (81 ± 11 vs 22 ± 7 ng/ml, P < 0.001), whereas cortico-
sterone concentrations were significantly decreased in IS (43 ±
14 ng/ml, P < 0.05) compared to IP. The two Sutherlandia-treated
groups did not differ (CS 57 ± 11 ng/ml). Neither testosterone nor
IL-6 and TNF- concentrations were significantly different among
groups. In summary, our data show that Sutherlandia frutescens
treatment effectively decreased the corticosterone response to
chronic stress, thereby scientifically confirming the indigenous
wisdom.
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The aim of this study was therefore to determine the effects of
daily treatment with an extract of Sutherlandia frutescens ssp.
microphylla on selected serum hormone (both anabolic and cata-
bolic) and cytokine levels, in a rat model of chronic immobiliza-
tion stress.
Methods
Experimental groups. Forty adult male Wistar rats (average body
mass of 376 ± 40 g at start of intervention protocol) were used in
this study. All rats were housed in groups of 4 in standard,
plastic-bottomed wire mesh cages with a 12 h:12 h light:dark
cycle. The animals were fed rat chow and tap water ad libitum. All
rats were allowed 4 weeks to acclimatize after transport to the
animal house, before the start of the stress intervention and
supplementation protocols.
Rats were separated into four mass-matched groups (10
animals in each group). Two groups represented the controls.
One of these received treatment with Sutherlandia extract (CS),
while the other received placebo (isotonic saline)(CP) for the
same period. The third and fourth groups were subjected to
chronic immobilization stress in addition to receiving either
Sutherlandia extract (IS) or placebo (IP).
Interventions. All rats were weighed and handled once a day
for 3 weeks before the start of the immobilization protocol to
accustom them to humans, preventing stress caused by (unac-
customed) handling being a confounding factor in this study.
Immobilization was achieved by placing rats individually into
small Perspex cages (8 × 6 × 18 cm) designed for this purpose,
which did not allow free movement. The duration of immobili-
zation sessions was 2 h, once daily, for 28 consecutive days.
Commercially available Sutherlandia is sold as 700-mg tablets,
each containing 300 mg Sutherlandia leaf powder. Manufacturers
of these tablets22 recommend a dose of one tablet twice daily. This
recommended dose of the commercial product equals 9 mg per
kg body mass for humans. This corresponds to a daily dose of
about 3.4 mg per rat, which was rounded up to 4 mg per rat, to
allow for weight gain during the study period. Specimens of
Sutherlandia were harvested in the vicinity of Murraysburg,
Western Cape province, South Africa, by W. Grobler. The plants
were identified as Sutherlandia frutescens subspecies microphylla
by B-E. van Wyk of the Botany Department, Rand Afrikaans Uni-
versity [voucher specimen from W. Grobler: C. Albrecht s.n sub.
B-E. van Wyk 4126 (JRAU)]. Since the traditional way of
administration is in the form of a herbal infusion, a warm water
extract was prepared: boiling water was added to dried Suther-
landia leaves (8 mg/ml) and left to infuse overnight at room tem-
perature. The infusion was not filtered, as this might have
resulted in removal of an active component, but poured through
a sieve to remove any relatively big leaf particles. Thereafter, the
extract was diluted 1:2 with 1.7% saline to produce an extract of
4 mg/ml in isotonic saline. Placebo consisted of a solution of
sterile 0.85% saline. Since the Sutherlandia extract has a bitter
taste, rats will not voluntarily ingest it, and forced oral adminis-
tration would represent an uncontrolled additional stressor.
Therefore, all rats were subjected to intraperitoneal injection
twice per day, of either 0.5 ml of 0.85% saline (CP and IP) or 0.5 ml
of Sutherlandia extract (CS and IS).
Sample collection. At the end of the protocol, all rats were
sacrificed between 11:00 and 13:00 by decapitation. The animals
were taken from the housing cage one at a time, placed into a
weighing basket and carried to another room, where they were
weighed and then decapitated. (The sacrifice process, from
removal from the cage to decapitation took less than one minute
per rat.) Whole blood, retrieved by exsanguination from the
aorta, was deposited into SST blood collection tubes (BD
Vacutainer Systems, Preanalytical Solutions, Plymouth, U.K.).
Blood was allowed to clot at room temperature for 10 min, after
which it was centrifuged at 3000 rpm for 10 min at 4°C, and the
serum aliquoted and frozen at –80°C until subsequent analysis.
Between consecutive sacrifices, all traces of blood and animal
waste were removed from the room, and the working area
disinfected with the chemical routinely used to clean housing
cages, to prevent acute stress in rats just prior to decapitation.
Analysis: Serum samples were analysed for corticosterone con-
centration by radio-immunoassay (Biotrak RPA 548, Amers-
ham), testosterone concentration by immunoassay (Advia
Centaur, Bayer Diagnostics) and IL-6 and TNF- concentrations
by ELISA (Biotrak RPN 2742 and RPN 2734, Amersham). Data
were analysed using two-way ANOVA with Fisher post hoc tests
to assess differences between subgroups. Relationships between
variables were assessed using Pearson correlations.
Results
The effects of Sutherlandia treatment, stress and interaction of
supplementation and stress on blood properties are illustrated
in Table 1 and Fig. 1a–c. Two-way ANOVA indicated no signifi-
cant main effect of Sutherlandia treatment alone. There was,
however, a significant primary effect of stress on both corti-
costerone (P < 0.05) and testosterone (P < 0.05) concentrations,
associated with a significant change in corticosterone:testoster-
one ratio (P < 0.01), as well as a significant effect of interaction
of stress and Sutherlandia treatment on serum corticosterone
concentration (P < 0.005) (Table 1).
Fisher ’s post hoc analysis indicated significantly increased
corticosterone concentration in IP vs CP (P < 0.001), and signifi-
cantly reduced corticosterone concentration in IS vs IP (P < 0.05;
Fig. 1a). Despite the (conservative) ANOVA result of no effect of
Sutherlandia treatment alone on corticosterone concentration,
which was probably the result of large inter-individual variations
in all four groups, post hoc analysis indicated that corticosterone
concentration was significantly higher in CS vs CP (P < 0.05;
Fig. 1a). Both CP and CS had significantly higher testosterone
concentrations than IS (P < 0.01 and P < 0.05; Fig. 1b), whereas
the corticosterone:testosterone ratio were significantly higher in
IP vs CP (P < 0.05; Fig. 1c).
IL-6 concentration showed a high level of inter-individual
variation and was not significantly different from the others in
any group (Fig. 2). TNF- concentration was below detectable
levels (<10 pg/ml) in all samples.
Discussion
Intermittent immobilization of rats is commonly used as a
means of inducing mild but physiologically significant stress.23–26
Therefore, the finding in the current study that stress significantly
increased basal serum corticosterone concentration (P < 0.05;
Table 1) was expected. Also, the finding that stress resulted in
decreased basal serum testosterone concentration (P < 0.05;
Table 1) is in accordance with results from previous studies.26–28
Table 1. Effects of stress, Sutherlandia treatment and interaction on concentra-
tions of parameters measured.
Corticosterone Testosterone C:T ratio* IL-6
Treatment n.s. n.s. n.s. n.s.
Stress P < 0.05 P < 0.05† P < 0.01 n.s.
Stress × treatment P < 0.005 n.s. n.s. n.s.
*Corticosterone:testosterone ratio.
†P-values were obtained by two-way ANOVA analysis.
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In addition, we present two main novel findings: First, that
Sutherlandia treatment decreased the corticosterone response to
chronic intermittent immobilization stress, and second, that
administration of the herb in control rats increased basal
corticosterone concentrations in these animals when compared
to placebo-supplemented rats as controls. The first main finding,
of an attenuated corticosterone response to stress, supports the
indigenous knowledge that Sutherlandia has stress-relieving
properties. However, further investigation is necessary to estab-
lish the exact mechanism by which this is achieved. Possible
target tissues for an anti-stress function of the herb include
the hypocampus (down-regulated stress perception), the hypo-
thalamus or pituitary gland (down-regulation of HPA-axis acti-
vation) and the adrenal gland (down-regulation of corticoste-
rone production). Since the herb has not been fully charac-
terized and the active ingredient(s) is not yet known, it is too
early to speculate further on possible mechanisms.
The second main finding has more than one possible explana-
tion. First, the herb was prepared in the traditional way, after
which it was filtered through a coarse sieve (pore size 0.5 mm),
but not sterilized, since sterilization at high temperature held the
possibility that an as yet unknown active substance may have
been inactivated. Similarly, filtration could possibly remove a
large molecule from the extract. The Sutherlandia infusion was
then administered by intraperitoneal injection, and not via the
upper digestive tract, as it would traditionally be ingested
(reasons discussed in methods section). The possibility therefore
exists that the herb may have elicited an inflammatory response,
resulting in increased basal corticosterone concentrations,
compared to placebo-controls, which received sterile saline.
However, IL-6 and TNF- concentrations in the treated control
rats were not significantly different from the other groups,
arguing against a chronic inflammatory state at the time of
sacrifice. A second, more likely explanation is that the Suther-
landia herb acts as an adaptogen (a substance increasing the
body’s ability to adapt and increase its resistance to stress and
disease, changing the course of an illness into a favourable out-
come by normalizing body functions), bringing about a more
functional basal corticosterone concentration through allostasis.
Allostasis is the term used to describe the process of maintaining
homeostasis by means of multiple interacting adaptive processes29
which may be achieved by combinations of mediators, produced
by the immune system, autonomic nervous system and the
HPA-axis.30,31The fact that the average basal corticosterone and
IL-6 concentrations in the two Sutherlandia groups were similar,
although one group was also subjected to immobilization stress,
supports this idea.
While acute stress is known to increase both IL-632,33 and
corticosterone levels,33,34, these increases in IL-6 levels are
inversely related to the raised glucocorticoid levels35 and
short-lived, due to the anti-inflammatory action of the enhanced
circulating corticosterone produced during stress.36 However,
chronic stress is known to result in glucocorticoid insensitivity of
monocytes, resulting in chronically increased IL-6 concentra-
tion.5 Our result of no significant difference in IL-6 concentration
between experimental groups seems to differ from the available
literature. However, taking into account the high inter-
individual variation reported for IL-6 in this study (Fig. 2) and in
the literature,37,38 the relatively small animal sample used in the
current study may have masked effects of Sutherlandia treatment
and chronic intermittent stress on secretion of IL-6. Further
studies on the acute cytokine responses to Sutherlandia adminis-
tration, possibly using larger sample numbers, are required to
investigate this possibility. Furthermore, the phasic release of
TNF- secretion, as well as its down-regulation by both IL-633,39
and glucocorticoids,40 may account for the non-detectable levels
of TNF- reported here.
The suppressive effect of stress alone on testosterone levels
(P < 0.05; Table 1) and the resultant effect of increasing the
corticosterone:testosterone ratio (P < 0.01; Table 1) may be due
to inhibition of the nocturnal rise in testosterone levels by
glucocorticoid action.41 Although Sutherlandia treatment did not
appear to have any direct effect on testosterone levels when
compared to control rats (Table 1 and Fig. 1b), small sample size
and large inter-individual variation may have masked such an
Fig. 1. Serum corticosterone concentration (a), testosterone concentration (b) and
corticosterone:testosterone ratio (c). Error bars indicate standard deviations.
P-values indicate significant differences obtained by Fisher post hoc analysis that
followed two-way ANOVA.
Fig. 2. Box-plot analysis of serum IL-6 concentrations. Boxes indicate mean ±
s.e.m., error bars indicate standard deviations, circles indicate outliers and
triangles indicate extreme outliers.
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effect in the current study. This issue warrants further investiga-
tion, since it is of particular importance in chronic illness to be
able to maintain testosterone levels, which is vital for tissue
growth and recovery.42,43
Conclusion
Our data for the first time confirm scientifically the indigenous
knowledge that the Sutherlandia frutescens herb has stress-reliev-
ing properties. In addition, our results indicate the necessity for
further investigations of the effects of this herb, since it appears
to have a complex mechanism of action and may therefore prove
to be appropriate for other illnesses as well.
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